← Human Trials & Peer-Reviewed Studies
Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial
Plain-language guide to PMID 30242948 (2019): double-blind randomized controlled trial study of Liraglutide, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 30242948
- Journal
- Diabetes, obesity & metabolism
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Liakos A et al. (11 authors)
- DOI
- 10.1111/dom.13541
What This Study Did, in Plain Language
What Was Tested
Researchers studied Liraglutide in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Eligible patients for this investigator-initiated, parallel-group, randomized, double-blind trial were on stable background antihyperglycaemic therapy excluding insulin, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.
Some participants received a placebo instead of Liraglutide, giving a reference point.
The Liraglutide group and the comparison group ran side by side rather than switching.
The primary outcome was change in 24-hour ambulatory systolic blood pressure (SBP), and secondary outcomes included change in ambulatory diastolic blood pressure (DBP) and heart rate.
The researchers also assessed renal sodium handling.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Blood Pressure, Blood Pressure Monitoring, Ambulatory, Diabetes Mellitus, Type 2, Heart Rate, Hypertension and Lipids.
Author keywords: GLP-1, liraglutide, randomized trial and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in people with low blood pressure and orthostatic hypotension.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Liraglutide compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.